Reply: Unblinding in the lecanemab trial in Alzheimer's disease

Brain. 2023 Nov 2;146(11):e101. doi: 10.1093/brain/awad201.

Authors

John Hardy^{1

2

3}, Catherine Mummery²

Affiliations

¹ Reta Lilla Weston Research Laboratories, UCL Institute of Neurology, London WC1N 3BG, UK.
² Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.
³ Dementia Research Institute, UCL Institute of Neurology, London WC1N 3BG, UK.

No abstract available

Publication types

Letter
Comment

MeSH terms

Alzheimer Disease* / drug therapy
Humans

Substances

lecanemab